• Tactile Systems Technology posted Q2 revenue up 9% to $85.7 million; GAAP net income more than doubled to $7.8 million.
• Gross margin widened 1 percentage point to 76%; adjusted EBITDA climbed to $11.4 million.
• Airway clearance revenue fell 7% on temporary inventory management dynamics tied to the next-generation AffloVest launch at some large DME providers.
• Entered an exclusive U.S. distribution deal with ElastiMed for MyoSleeve to VA/DoD channels; launched the next-generation AffloVest system.
• Trimmed 2026 revenue outlook to $360 million-$366 million; maintained adjusted EBITDA forecast of $49 million-$51 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tactile Systems Technology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-093346), on August 10, 2026, and is solely responsible for the information contained therein.